Response Assessment With Molecular Characterization of Circulating Tumor Cells and Plasma MicroRNA Profiling in Patients With Locally Advanced Breast Cancer During Neoadjuvant Chemotherapy
- 1 August 2020
- journal article
- research article
- Published by Elsevier in Clinical Breast Cancer
- Vol. 20 (4) , 332-343.e3
Abstract
No abstract availableKeywords
Funding Information
- Türkiye Bilimsel ve Teknolojik Araştırma Kurumu (SBAG-115S272)
This publication has 48 references indexed in Scilit:
- miRDeep*: an integrated application tool for miRNA identification from RNA sequencing dataNucleic Acids Research, 2012
- STAR: ultrafast universal RNA-seq alignerBioinformatics, 2012
- Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cellsBreast Cancer Research, 2012
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trialThe Lancet Oncology, 2012
- Plasma microRNAs as potential biomarkers for non-small-cell lung cancerLaboratory Investigation, 2011
- Expression of epithelial–mesenchymal transition‐inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapyInternational Journal of Cancer, 2011
- Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancerBreast Cancer Research, 2010
- Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patientsBreast Cancer Research, 2009
- Models, mechanisms and clinical evidence for cancer dormancyNature Reviews Cancer, 2007
- Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast CancerNew England Journal of Medicine, 2004